🔗 Share this article Patients Coming Off Anti-Obesity Jabs Put On Weight Far More Rapidly Compared to People Using Diet and Exercise Weight management often requires long-term strategies. New research indicates that individuals who stop using blockbuster weight-loss injections like semaglutide or tirzepatide can put back on lost weight far faster than those who stop traditional diet and exercise regimens. Research printed in a prominent medical journal demonstrates that while obese individuals frequently drop about a fifth of their body weight while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation. "Individuals using such treatments should be informed of the potential of rapid weight regain when the therapy is stopped," cautioned expert Dr. Susan Jebb. Such speed of regain suggests a return to starting weight in about 18 months. Analyzing Approaches The study, which looked at dozens of trials involving thousands of participants, compared the outcomes of these new drugs with older methods. The team note that individuals who shed pounds through lifestyle changes alone generally have a slower creep back—approximately 0.1 kg a month—after stopping. Understanding the Rapid Rebound Doctors believe the mode of action of the jabs explains the amplified regain. The injections mimic a natural hormone called GLP-1, which controls feelings of fullness. "Long-term administration of GLP-1 concentrations far above than normal could lead to the body to produce less of its own natural hormone, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert. "Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making binge eating much more probable." A Chronic Condition? Health authorities recommend the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes. Professionals say that, considering the significant potential of weight regain, the therapy should be considered long-term. This opinion is reinforced by pharmaceutical companies, who note that the findings "underscore the chronic nature of obesity," comparing it to managing diseases like high blood pressure. Patient Accounts Users who have come off the jabs explain a powerful resurgence of hunger. "It was like a switch flipping and you become starving," recalled an individual. This difficulty is worsened if users have not developed permanent dietary or behavioural changes during therapy. Widespread Use Figures suggest that millions of people in the UK have tried these injections in the past year, with desire continuing to grow. Adoption is more common among females compared to males. The middle-aged demographic shows the highest level of interest. Many access the drugs through private healthcare rather than public health services. Ultimately, clinicians caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic cure and lasting health benefits hinges on combined lifestyle support.
Weight management often requires long-term strategies. New research indicates that individuals who stop using blockbuster weight-loss injections like semaglutide or tirzepatide can put back on lost weight far faster than those who stop traditional diet and exercise regimens. Research printed in a prominent medical journal demonstrates that while obese individuals frequently drop about a fifth of their body weight while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation. "Individuals using such treatments should be informed of the potential of rapid weight regain when the therapy is stopped," cautioned expert Dr. Susan Jebb. Such speed of regain suggests a return to starting weight in about 18 months. Analyzing Approaches The study, which looked at dozens of trials involving thousands of participants, compared the outcomes of these new drugs with older methods. The team note that individuals who shed pounds through lifestyle changes alone generally have a slower creep back—approximately 0.1 kg a month—after stopping. Understanding the Rapid Rebound Doctors believe the mode of action of the jabs explains the amplified regain. The injections mimic a natural hormone called GLP-1, which controls feelings of fullness. "Long-term administration of GLP-1 concentrations far above than normal could lead to the body to produce less of its own natural hormone, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert. "Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making binge eating much more probable." A Chronic Condition? Health authorities recommend the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes. Professionals say that, considering the significant potential of weight regain, the therapy should be considered long-term. This opinion is reinforced by pharmaceutical companies, who note that the findings "underscore the chronic nature of obesity," comparing it to managing diseases like high blood pressure. Patient Accounts Users who have come off the jabs explain a powerful resurgence of hunger. "It was like a switch flipping and you become starving," recalled an individual. This difficulty is worsened if users have not developed permanent dietary or behavioural changes during therapy. Widespread Use Figures suggest that millions of people in the UK have tried these injections in the past year, with desire continuing to grow. Adoption is more common among females compared to males. The middle-aged demographic shows the highest level of interest. Many access the drugs through private healthcare rather than public health services. Ultimately, clinicians caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic cure and lasting health benefits hinges on combined lifestyle support.